http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-0880540-B1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_c4180fc57a693864e2ce2dbfd64a9278 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07J73-005 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07J73-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-59 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-59 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P43-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07J73-00 |
| filingDate | 1997-01-09-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2002-06-12-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_34aa012e265c7ddfc6b5ba8dbd77705c http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d4b614dcf0e29a32060c8dbe11283726 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_2fa354b4518a79464064e5ea89ac36ba |
| publicationDate | 2002-06-12-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | EP-0880540-B1 |
| titleOfInvention | 17-beta-cyclopropyl(amino/oxy) 4-aza steroids as active inhibitors of testosterone 5-alpha-reductase and c17-20-lyase |
| abstract | The invention related to 4-aza-17 beta -(cyclopropoxy)-androst-5 alpha -androstan-3-one, 4-aza-17 beta -(cyclopropylamino)-androst-4-en-3-one and related compounds and to compositions incorporating these compounds, as well as the inhibition of C17-20 lyase, 5 alpha -reductase and C17 alpha -hydroxylase and to the use of these compounds in the treatment of androgen and estrogen mediated disorders, including benign prostatic hyperplasia, androgen mediated prostate cancer, estrogen mediated breast cancer and to DHT-mediated disorders such as acne. Disorders relating to the oversynthesis of cortisol, for example, Cushing's Syndrome, are also included. The treatment of androgen-dependent disorders also includes a combination therapy with known androgen-receptor antagonists, such as flutamide. The compounds of the invention have general formula (I). |
| isCitedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2481107-C2 |
| priorityDate | 1996-02-14-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 917.